Aaron Lorenzo

Three-Year Data Suggest Broader Provenge Label In Prostate Cancer

Oct. 29, 2004

Boosting hopes for a wider label than previously thought, Dendreon Corp. released final three-year follow-up data from a Phase III study of Provenge. (BioWorld Today)

Pharmasset, Roche Sign HCV Agreement Worth Up To $300M

Oct. 28, 2004

By Aaron Lorenzo

Pharmasset Inc. could receive up to $168 million in milestone payments and maybe much more, after licensing its preclinical hepatitis C drug program to F. Hoffmann-La Roche Ltd. (BioWorld Today)

Pharmasset, Roche Sign HCV Agreement Worth Up To $300M

Oct. 28, 2004

By Aaron Lorenzo

Pharmasset Inc. could receive up to $168 million in milestone payments and maybe much more, after licensing its preclinical hepatitis C drug program to F. Hoffmann-La Roche Ltd. (BioWorld Today)

Aaron Lorenzo

ARTICLES

Three-Year Data Suggest Broader Provenge Label In Prostate Cancer

Pharmasset, Roche Sign HCV Agreement Worth Up To $300M

Pharmasset, Roche Sign HCV Agreement Worth Up To $300M

EntreMed Partners TFPI Program With Affymax

EntreMed Partners TFPI Program With Affymax

Pharmacopeia, Neurocrine Agree To Expand Discovery Relationship

Pharmacopeia, Neurocrine Agree To Expand Discovery Relationship

Shares Of Dyax Plummet As FDA Delays DX-88 Program

Shares Of Dyax Plummet As FDA Delays DX-88 Program

Positive Phase III CTLA4-Ig Data Bump Repligen's Stock

Today's news in brief

Today's news in brief

News in brief

Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody

KT-621: a first-in-class STAT6 degrader for Th2-driven diseases